Related Experiment Videos
Vascular targeting agents.
Mary Jo Pilat1, Julie McCormick, Patricia Mucci LoRusso
1Karmanos Cancer Institute, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA.
Current Oncology Reports
|January 31, 2004
Summary
Vascular targeting agents (VTAs) offer new strategies to combat cancer by disrupting tumor blood vessels, leading to tumor cell death. These agents show promise alone or in combination therapies for improved antitumor effects.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Tumor vascular networks are crucial for cancer growth and survival.
- Early research focused on inhibiting new blood vessel formation (angiogenesis).
- Current strategies aim to destroy existing tumor blood vessels.
Purpose of the Study:
- To review the development and therapeutic potential of vascular targeting agents (VTAs).
- To discuss the mechanisms of action for VTAs in cancer treatment.
- To explore the efficacy of VTAs as monotherapy and in combination regimens.
Main Methods:
- Review of current literature on vascular targeting agents.
- Analysis of therapeutic strategies targeting tumor vasculature.
- Examination of clinical trial data for VTAs.
Main Results:
- Vascular targeting agents (VTAs) rapidly shut down tumor blood flow, causing ischemia and necrosis.
- VTAs are broadly classified into biologic agents and small molecules.
- Drug-based VTAs have advanced significantly, with numerous ongoing clinical trials.
Conclusions:
- VTAs represent a promising therapeutic approach for cancer treatment.
- Evidence suggests VTAs are effective as single agents and potentially more so in combination therapies.
- Further research and clinical trials are warranted to optimize VTA utilization in cancer regimens.